[Secondary prevention of TIA and stroke. How much must thrombocytes not be inhibited?].
Einecke
Dirk
D
D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D002544:Cerebral Infarction / Q000097:blood / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D002546:Ischemic Attack, Transient / Q000097:blood / Q000517:prevention & control*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D012306:Risk; D055502:Secondary Prevention; D013988:Ticlopidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin
TIA- und Schlaganfall-Sekundärprophylaxe. Wie stark muss man jetzt die Thrombozyten hemmen?